Phio Pharmaceuticals
PHIO
11 hedge funds and large institutions have $387K invested in Phio Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 4 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
196% more capital invested
Capital invested by funds: $131K → $387K (+$257K)
1.33% more ownership
Funds ownership: 2.11% → 3.43% (+1.3%)
0% more funds holding
Funds holding: 11 → 11 (0)
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$98.5K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$32.6K |
| 3 |
VF
Virtu Financial
New York
|
+$28.9K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$7.01K |
| 5 |
SS
SBI Securities
Tokyo,
Japan
|
+$1.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$14K |
| 2 |
Cetera Investment Advisers
Schaumburg,
Illinois
|
-$12.1K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$3.25K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$134 |
| 5 |
Barclays
London,
United Kingdom
|
-$7 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Geode Capital Management
Boston,
Massachusetts
| $136K | +$32.6K | +16,108 | +39% |
|
|
2
Vanguard Group
Malvern,
Pennsylvania
| $114K | +$98.5K | +48,665 | New |
|
|
3
Cetera Investment Advisers
Schaumburg,
Illinois
| $76.4K | -$12.1K | -6,000 | -16% |
|
|
VF
4
Virtu Financial
New York
| $34K | +$28.9K | +14,298 | New |
|
5
Morgan Stanley
New York
| $14.1K | – | – | – |
|
|
6
Royal Bank of Canada
Toronto,
Ontario, Canada
| $8K | +$7.01K | +3,464 | New |
|
|
SS
7
SBI Securities
Tokyo,
Japan
| $4.49K | +$1.9K | +941 | +97% |
|
8
AssetMark Inc
Concord,
California
| $259 | – | – | – |
|
9
Bank of America
Charlotte,
North Carolina
| $108 | +$10 | +5 | +12% |
|
|
MYIA
10
Mount Yale Investment Advisors
Denver,
Colorado
| $63 | +$55 | +27 | New |
|
|
AWM
11
Activest Wealth Management
Aventure,
Florida
| $21 | – | – | – |
|
|
XT
12
XTX Topco
George Town,
Cayman Islands
| – | -$14K | -10,800 | Closed |
|
|
TRCT
13
Tower Research Capital (TRC)
New York
| – | -$3.25K | -2,501 | Closed |
|
|
14
UBS Group
Zurich,
Switzerland
| – | -$134 | -103 | Closed |
|
|
15
Barclays
London,
United Kingdom
| – | -$7 | -5 | Closed |
|
PHIO Hedge Fund Activity: Q2 2025 in Review
11 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Phio Pharmaceuticals (PHIO) for Q2 2025, worth a combined $387K — up 196% from $131K a quarter earlier.
Fund positioning in PHIO was balanced in Q2 2025: 4 funds opened new positions, 4 closed out, 3 added to existing stakes and 1 trimmed.
The largest buyer was Vanguard Group, opening a new position worth an estimated $98.5K. The largest seller was XTX Topco, exiting entirely with an estimated $14K sold.
- 11 institutional investors held Phio Pharmaceuticals (PHIO) as of Q2 2025, unchanged from Q1 2025.
- Funds reported $387K of Phio Pharmaceuticals stock for Q2 2025, up 196% quarter-over-quarter.
- 4 funds opened new Phio Pharmaceuticals positions in Q2 2025 and 4 closed out, a net change of 0 holders.
- The largest Phio Pharmaceuticals buyer in Q2 2025 was Vanguard Group, an estimated $98.5K added.
- The largest Phio Pharmaceuticals seller in Q2 2025 was XTX Topco, an estimated $14K sold.
Based on aggregated 13F filings for Q2 2025.